Trial NCT03894007

View at ClinicalTrials.gov 
Org. Study IDs: PREDIX II HER2
Secondary IDs: 2018-004457-24

Last trial update was posted on 2021-09-23

MeSH Interventions

Ado-Trastuzumab Emtansine Atezolizumab Carboplatin Cyclophosphamide Docetaxel Epirubicin Maytansine Pertuzumab Trastuzumab

MeSH Conditions

Breast Neoplasms

Other Conditions

Early-stage Breast Cancer HER2-positive Breast Cancer

Stopping Reasons

Security and effect data from another ongoing study.

Limitations And Caveats

N/A

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID